Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Next Previous
Trial Profile

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Intravenous Therapy in Patients With Prosthetic Joint Infections

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fusidic acid (Primary) ; Antibacterials; Antibacterials; Rifampicin
  • Indications Bone and joint infections; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Arrevus; Cempra Pharmaceuticals

    • Most Recent Events

    • 28 Sep 2016 Results of this trial, published in the Clinical Infectious Diseases journal.
    • 17 Apr 2015 According to a Cempra Pharmaceuticals media release, results from this trial will be presented at the 25th European Congress of Clinical Microbiology (ECCMID).
    • 09 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top